Computational Analysis of HLA-presentation of Non-synonymous Recipient Mismatches Indicates Effect on the Risk of Chronic Graft-vs.-Host Disease After Allogeneic HSCT

Frontiers in Immunology
Jarmo RitariJ Partanen

Abstract

Genetic mismatches in protein coding genes between allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipient and donor can elicit an alloimmunity response via peptides presented by the recipient HLA receptors as minor histocompatibility antigens (mHAs). While the impact of individual mHAs on allo-HSCT outcome such as graft-vs.-host and graft-vs.-leukemia effects has been demonstrated, it is likely that established mHAs constitute only a small fraction of all immunogenic non-synonymous variants. In the present study, we have analyzed the genetic mismatching in 157 exome-sequenced sibling allo-HSCT pairs to evaluate the significance of polymorphic HLA class I associated peptides on clinical outcome. We applied computational mismatch estimation approaches based on experimentally verified HLA ligands available in public repositories, published mHAs, and predicted HLA-peptide affinites, and analyzed their associations with chronic graft-vs.-host disease (cGvHD) grades. We found that higher estimated recipient mismatching consistently increased the risk of severe cGvHD, suggesting that HLA-presented mismatching influences the likelihood of long-term complications in the patient. Furthermore, computational approaches fo...Continue Reading

References

Feb 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·W A Erik MarijtJ H Frederik Falkenburg
Apr 30, 2003·Protein Science : a Publication of the Protein Society·Morten NielsenOle Lund
Mar 7, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nathan J RobertsonJulian Dyson
Apr 18, 2007·Nature Reviews. Immunology·Warren D Shlomchik
Mar 14, 2009·Lancet·James L M FerraraErnst Holler
Nov 26, 2009·Nature Genetics·Steven A McCarrollDavid Altshuler
Apr 1, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Malene Erup LarsenLars Vindelov
Apr 10, 2010·Immunogenetics·Thomas StranzlMorten Nielsen
Apr 23, 2010·Immunology·Morten NielsenClaus Lundegaard
Nov 26, 2010·Nature Reviews. Genetics·Joshua B Plotkin, Grzegorz Kudla
Jan 14, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J H Frederik Falkenburg, Edus H Warren
Oct 2, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Willemijn HoboHarry Dolstra
Jun 13, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Eric SpieringsEls Goulmy
Nov 10, 2013·PLoS Computational Biology·Jorg J A CalisBjoern Peters
Dec 10, 2013·Nucleic Acids Research·Paul FlicekStephen M J Searle
Apr 10, 2014·Nature Communications·Diana Paola GranadosClaude Perreault
Oct 11, 2014·Nucleic Acids Research·Randi VitaBjoern Peters
Nov 29, 2014·Current Protocols in Bioinformatics·Geraldine A Van der AuweraMark A DePristo
Jan 24, 2015·Science·Mathias UhlénFredrik Pontén
Apr 4, 2015·Science·Ton N Schumacher, Robert D Schreiber
Mar 26, 2016·Frontiers in Immunology·Marieke GriffioenJ H Frederik Falkenburg
Nov 21, 2017·Nucleic Acids Research·Daniel R ZerbinoPaul Flicek
Nov 15, 2018·Genome Biology·Michelle S KimJoseph Lachance

❮ Previous
Next ❯

Methods Mentioned

BETA
exome sequencing

Software Mentioned

predict
_ . py
Genotype Analysis Tool Kit ( GATK )
Ensembl
Omixon Explore
Assign
Immunogenicity -
tidyverse
Biostrings
R

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.